LadRx Corporation (OTCPK: LADX)
Health Care · Biotechnology · US
$—
— today · — 1Y
LadRx Corporation (OTCPK: LADX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $5.45K and employs 2 people.
trading between 0.00 and 2.20.
Tweenvest scores LadRx Corporation across four factors: quality 27/100. Its strongest factor is quality.
LADX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $5.45K
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -5.04
- Dividend yield
- —
- Beta (5Y)
- 1.31
- 52-week high
- $2.20
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 495.09K
- Employees
- 2
- Next earnings
- —
About LadRx Corporation
LadRx Corporation, a biopharmaceutical company, engages in research and development of chemotherapeutic drugs for solid tumors in the United States. The company offers linker activated drug releases (LADR) technology, a platform consists of an organic backbone that is attached to a chemotoxic agent that targets and delivers the chemotoxic agent to the tumor environment and release within the tumor. Its lead candidates comprising LADRs 7, 8, 9, and 10 with novel derivatives of the auristatin and maytansinoid drug targeting tumors; and aldoxorubicin, which is in phase II clinical development for the treatment of pancreatic cancer. In addition, the company develops albumin companion diagnostic (ACDx) to identify patients with cancer that benefits from treatment with the four LADR lead candidates. The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. The company was incorporated in 1985 and is headquartered in Los Angeles, California.
- ISIN
- US2328287071
- Founded
- 1985
- Listed since
- Mar 29, 1989
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.